Immunomedics Develops Two New Drug Immunoconjugates For Targeted Therapy Of Colon And Lung Cancers

SAN FRANCISCO -- Immunomedics, Inc., a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today reported the development of two new antibody-drug conjugates, potentially for the therapy of colon and lung cancers, at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications, in San Francisco, CA. The antibodies selected for this study were hMN-14, a non-internalizing humanized antibody that binds to the carcinoembryonic antigen (CEACAM5) expressed by many solid cancers, and hRS7, a rapidly internalizing humanized antibody targeting epithelial glycoprotein-1 (EGP-1) expressed in high a...